---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030102"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:36:51.860817+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharma enters 12-month option for castanospermine license with Florida State

## Summary
- Entered exclusive 12-month option to negotiate a royalty-bearing license for castanospermine purification technology.
- Company holds 8.8 kg of Australian Chestnut extract inventory for potential botanical product commercialization.
- Castanospermine is a bioactive alkaloid; company already owns IP on synthetic derivative celgosivir for viral diseases.
- Company states the option agreement is not material to its business or operations.
- Intends to explore non-prescription botanical extracts under changing U.S. regulatory framework.

## SEC filing metadata
- accession: 0001213900-25-030102
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390025030102/0001213900-25-030102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390025030102/ea0237280-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030102
- JSON: https://secwatch.observer/filing/0001213900-25-030102.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.